Literature DB >> 25298044

Changing microbial epidemiology in hematopoietic stem cell transplant recipients: increasing resistance over a 9-year period.

N Macesic1, C O Morrissey, A C Cheng, A Spencer, A Y Peleg.   

Abstract

UNLABELLED: Infections remain important contributors to mortality in hematopoietic stem cell transplantation (HSCT).
METHOD: We studied the evolving epidemiology and trends in susceptibility of bacterial and Candida isolates at an Australian HSCT center. A total of 528 HSCTs in 508 patients were performed from April 2001 to May 2010. A total of 605 isolates were eligible for study inclusion; 318 (53%) were gram-positive, 268 (44%) were gram-negative, and 19 (3%) were Candida species.
RESULTS: The most common site for isolates was blood (380 isolates, 63%). Staphylococcus aureus was the most common gram-positive organism (n = 107, 34%), but trends to increasing coagulase-negative staphylococci (P = 0.002) and vancomycin-resistant Enterococcus (P < 0.001) were observed. Escherichia coli was the most common gram-negative isolate (n = 74, 28%). Fluoroquinolone resistance increased with widespread use of protocol fluoroquinolone prophylaxis (P = 0.001). Carbapenem resistance was found in 44% of Pseudomonas or Acinetobacter isolates. Bloodstream infection with a multidrug-resistant organism (odds ratio 3.61, 95% confidence interval: 1.40-9.32, P = 0.008) was an independent predictor of mortality at 7 days after a positive blood culture.
CONCLUSIONS: Antimicrobial resistance is an increasing problem in this vulnerable patient population, and not only has an impact on choice of empiric therapy for febrile neutropenia but also on mortality.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Candida; bacteria; epidemiology; hematopoietic stem cell transplantation; infection; microbial drug resistance

Mesh:

Substances:

Year:  2014        PMID: 25298044     DOI: 10.1111/tid.12298

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  24 in total

1.  Changes in bacterial epidemiology and antibiotic resistance among veterans with spinal cord injury/disorder over the past 9 years.

Authors:  Margaret A Fitzpatrick; Katie J Suda; Nasia Safdar; Stephen P Burns; Makoto M Jones; Linda Poggensee; Swetha Ramanathan; Charlesnika T Evans
Journal:  J Spinal Cord Med       Date:  2017-02-15       Impact factor: 1.985

2.  Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation.

Authors:  Michael J Satlin; Santosh Vardhana; Rosemary Soave; Tsiporah B Shore; Tomer M Mark; Samantha E Jacobs; Thomas J Walsh; Usama Gergis
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-03       Impact factor: 5.742

3.  Impact of antibacterial prophylaxis during reinduction chemotherapy for relapse/refractory acute myeloid leukemia.

Authors:  Beejal R Ganti; Bernard L Marini; Jerod Nagel; Dale Bixby; Anthony J Perissinotti
Journal:  Support Care Cancer       Date:  2016-10-14       Impact factor: 3.603

4.  High Levels of Morbidity and Mortality Among Pediatric Hematopoietic Cell Transplant Recipients With Severe Sepsis: Insights From the Sepsis PRevalence, OUtcomes, and Therapies International Point Prevalence Study.

Authors:  Robert B Lindell; Shira J Gertz; Courtney M Rowan; Jennifer McArthur; Florian Beske; Adrian Plunkett; Scott L Weiss; Neal J Thomas; Vinay M Nadkarni; Julie C Fitzgerald
Journal:  Pediatr Crit Care Med       Date:  2017-12       Impact factor: 3.624

5.  Bacteremia during neutropenic episodes in children undergoing hematopoietic stem cell transplantation with ciprofloxacin and penicillin prophylaxis.

Authors:  Worawut Choeyprasert; Suradej Hongeng; Usanarat Anurathapan; Samart Pakakasama
Journal:  Int J Hematol       Date:  2016-10-22       Impact factor: 2.490

6.  Incidence rate of fluoroquinolone-resistant gram-negative rod bacteremia among allogeneic hematopoietic cell transplantation patients during an era of levofloxacin prophylaxis.

Authors:  Arianna Miles-Jay; Susan Butler-Wu; Ali Rowhani-Rahbar; Steven A Pergam
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-11       Impact factor: 5.742

Review 7.  Rethinking Antimicrobial Prophylaxis in the Transplant Patient in the World of Emerging Resistant Organisms-Where Are We Today?

Authors:  Lucy E Horton; Nina M Haste; Randy A Taplitz
Journal:  Curr Hematol Malig Rep       Date:  2018-02       Impact factor: 3.952

8.  Current State of Antimicrobial Stewardship at Solid Organ and Hematopoietic Cell Transplant Centers in the United States.

Authors:  Susan K Seo; Kaming Lo; Lilian M Abbo
Journal:  Infect Control Hosp Epidemiol       Date:  2016-07-26       Impact factor: 3.254

9.  Antibiotics in Hematopoietic Cell Transplantation: Adversaries or Allies?

Authors:  Tessa M Andermann; Ami S Bhatt
Journal:  Biol Blood Marrow Transplant       Date:  2016-04-14       Impact factor: 5.742

10.  Levofloxacin Prophylaxis During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia.

Authors:  Joshua Wolf; Li Tang; Patricia M Flynn; Ching-Hon Pui; Aditya H Gaur; Yilun Sun; Hiroto Inaba; Tracy Stewart; Randall T Hayden; Hana Hakim; Sima Jeha
Journal:  Clin Infect Dis       Date:  2017-11-13       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.